source
- Moderna sticks to 10% revenue growth goal despite Phase 3 norovirus vaccine missModerna said it will continue to aim for up to 10% revenue growth this year, even though its experimental norovirus vaccine did not achieve statistical significance in a Phase 3 interim analysis.…
- Moderna delays norovirus vaccine readout, cites insufficient infectionsModerna announced that its norovirus vaccine trial will not yield efficacy data this season because infection rates were lower than expected. The company said it will open an additional trial coho…